ArticleDiabetes2026
Islet-Targeted ZnT8 Antibodies Protect Pancreatic β-Cells From Inflammatory Stress.
Article in Diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
β-Cell maladaptive unfolded protein response is a shared pathogenic feature of type 1 and type 2 diabetes, yet therapeutic strategies that selectively restore β-cell proteostasis remain limited. Zinc transporter 8 (ZnT8) is an islet-restricted endoplasmic reticulum (ER)-resident membrane protein whose folding burden is amplified under inflammatory stress. Here, we show that cell surface-directed ZnT8 antibodies are internalized and act as selective ZnT8 chaperones, preserving β-cell function across multiple diabetes models. ZnT8 chaperoning protected β-cells in prediabetic autoimmune nonobese diabetic (NOD) mice and obesity-associated diabetic mice on an inflammation-prone background, suppressing maladaptive ER stress and MHC class I hyperexpression. In contrast, no protection was observed in inflammation-resistant obesity-associated diabetes or in models of ZnT8-independent proteotoxicity or direct β-cell cytotoxicity, indicating that ZnT8 chaperoning is contingent on ZnT8-associated inflammatory stress. A humanized Fc-silent derivative, Isle43, showed durable pancreatic retention, dose-dependent reversal of new-onset type 1 diabetes in NOD mice, and sustained remission after treatment cessation. In isolated human islets, ZnT8 chaperoning preserved cytokine-induced reductions in ZnT8 and insulin while attenuating HLA class I and binding immunoglobulin protein induction. Notably, programmed death-ligand 1 (PD-L1) was robustly induced independently of cytokine exposure, identifying PD-L1 as a marker of ZnT8 chaperoning. In vivo, Isle43 accumulated in transplanted human islets and preserved graft-dependent glycemic control in diabetic NOD severe combined immunodeficiency recipients. Together, these findings identify ZnT8 folding burden as a key determinant of β-cell proteostasis under inflammatory stress and define islet-targeted ZnT8 chaperoning as a precision strategy for preserving β-cell function in inflammation-dependent diabetes. ARTICLE HIGHLIGHTS: Inflammatory stress increases endoplasmic reticulum protein-folding burden in β-cells and amplifies immunogenicity through HLA-I hyperexpression, yet targeted strategies to restore β-cell proteostasis are lacking. We demonstrate that an islet-specific, cell surface-directed antibody is internalized and functions as a zinc transporter 8-selective chaperone, enhancing endoplasmic reticulum folding capacity, attenuating HLA-I hyperexpression, and robustly inducing programmed death-ligand 1. Identification of programmed death-ligand 1 as a direct pharmacodynamic marker of zinc transporter 8-chaperoning links on-target engagement to reinforcement of local immune checkpoint signaling. Humanized Fc-silent Isle43 shows durable pancreatic retention, dose-dependent reversal of new-onset type 1 diabetes in nonobese diabetic mice, sustained remission after treatment cessation, and protection of human islet graft function in vivo. This islet-targeted strategy preserved β-cell function in inflammatory mouse models and human islet grafts, supporting an islet-targeted therapeutic approach for inflammatory β-cell failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.